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Abstract
To quantify the impact of cardiac motion on stent length measurements with Optical Coherence Tomography (OCT) and 
to demonstrate in vivo OCT imaging of implanted stents, without motion artefacts. The study consists of: clinical data 
evaluation, simulations and in vivo tests. A comparison between OCT-measured and nominal stent lengths in 101 clinically 
acquired pullbacks was carried out, followed by a simulation of the effect of cardiac motion on stent length measurements, 
experimentally and computationally. Both a commercial system and a custom OCT, capable of completing a pullback between 
two consecutive ventricular contractions, were employed. A 13 mm long stent was implanted in the left anterior descending 
branch of two atherosclerotic swine and imaged with both OCT systems. The analysis of the clinical OCT images yielded 
an average difference of 1.1 ± 1.6 mm, with a maximum difference of 7.8 mm and the simulations replicated the statistics 
observed in clinical data. Imaging with the custom OCT, yielded an RMS error of 0.14 mm at 60 BPM with the start of the 
acquisition synchronized to the cardiac cycle. In vivo imaging with conventional OCT yielded a deviation of 1.2 mm, rela-
tive to the length measured on ex-vivo micro-CT, while the length measured in the pullback acquired by the custom OCT 
differed by 0.20 mm. We demonstrated motion artefact-free OCT-imaging of implanted stents, using ECG triggering and a 
rapid pullback.
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Introduction
Percutaneous coronary intervention is the standard proce-
dure for the treatment of acute coronary syndrome. The 
procedure is carried out under X-ray angiography guidance 
to visualize the coronary artery lumina. Yet, X-ray angiog-
raphy has some limitations: it provides 2D projections of a 
3D structure, it gives no information about the vessel wall 
geometry and composition, and it has a limited resolution 
[1]. These limitations can be overcome with intravascular 
imaging: intravascular ultrasound (IVUS) [2] and optical 
coherence tomography [3–7] (OCT) are commercially avail-
able modalities.
These technologies provide detailed imaging of the inside 
of the coronary vasculature, which has led to improved clini-
cal outcomes in terms of major adverse cardiac events and 
even mortality [8], immediately and in the long term [9–13], 
and of post-procedure fractional flow reserve (FFR) [14].
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Among the imaging technologies available, OCT offers, 
with an axial resolution of 20 µm, the highest amount of 
detail to visualize the vessel wall morphology. However, 
motion artefacts generated by ventricular contractions dur-
ing imaging and undersampling in the pullback direction can 
affect the OCT volumetric renderings [15]. These artefacts 
occur as the pullback speed and frame rate dictate that a pull-
back acquisition is performed over 2–3 s, during which the 
heart beats a few times. Longitudinal and transverse motion 
of the catheter relative to the vessel under study may gener-
ate deformations in the imaged volume [16] that can affect 
local measurements of for instance plaque length, which may 
affect stent selection. Undersampling results from the frame 
pitch being greater than the lateral image resolution, and 
leads to a disconnected appearance of microscopic features 
along the pullback [17]. A previous realization of high-speed 
OCT stent imaging demonstrated artefacts in the rendered 
stent originating in cardiac motion, but could not address 
undersampling due to limitations in frame rate [18].
In this study, we quantified the effects of motion arte-
facts on OCT image quality and assessed whether ECG 
triggering, together with high acquisition speed, mitigated 
these effects. The study consists of three parts: we assessed 
the effect of cardiac motion by comparing the longitudinal 
geometric measure of implanted coronary stents with their 
nominal lengths [19] in clinical data. We then replicated the 
observed length mismatches in a cardiac motion simulation, 
evaluating the effect of ECG triggering and very fast pull-
backs, compared to conventional acquisitions, in a bench-
top experiment. Finally, we compared the lengths of stents 
implanted in a large atherosclerotic animal model in vivo 
with the two versions of OCT imaging.
Methods
Quantification of OCT‑measured length mismatch 
in clinical data
The influence of motion artefacts in OCT images of 
implanted coronary stents was assessed by comparing the 
lengths of implanted stents as measured by OCT with their 
nominal lengths. OCT data were gathered from the clini-
cal database at Erasmus MC. A total of 101 pullbacks (101 
patients; 61 LAD, 16 LCX, 23 RCA and 1 diagonal branch), 
acquired with a commercial OCT system (Ilumien™ 
Optis™, Abbott, Abbott Park, Illinois, USA) during PCI 
directly after implantation of a single stent, were included. 
All data sets were acquired with calibrated Z-offsets and had 
good flush quality. Measurements were made by a trained 
observer, who was blinded to the nominal lengths. The stent 
lengths were calculated by counting the total number of 
frames that contained at least one stent strut, consistent with 
clinical practice, and multiplying by the frame pitch as speci-
fied by the manufacturer. Subsequently, the OCT-measured 
lengths were compared with the nominal measures.
The data were processed using regression analysis to 
study the relation between OCT-measured stent lengths and 
nominal lengths.
Preclinical OCT imaging
We implemented an OCT system, which we have called 
Heartbeat OCT (Fig. 1), that acquires data approximately 
15 times faster than conventional OCT (A-scan rate of 
1.55 MHz, compared to about 100 kHz in commercial sys-
tems) and 6 times than other prototypes [18], which enables 
imaging at 3000 frames per second (fps) in a pullback at 
100 mm/s, compared to 180 fps and 36 mm/s of commercial 
systems. The Heartbeat OCT was previously described in 
detail [16, 20]. It relies on three key elements: (1) a Fou-
rier Domain Mode Locked (FDML) laser [21], (2) a distally 
Fig. 1  Heartbeat OCT sche-
matic: image acquisition is 
triggered by the ECG signal, 
completing the scan of the 
coronary artery between two 
subsequent heart contractions
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actuated imaging catheter [22] and (3) ECG triggering of 
the scan. This scan sequence enables imaging of a relevant 
section of the coronary artery during the diastolic phase of 
the cardiac cycle, when there is no rapid tissue motion due 
to ventricular contraction.
For reference, a conventional OCT system was used.
Cardiac motion simulation
Numerical simulation
The variable position of a stented vessel due to cardiac 
motion was numerically simulated as a one-dimensional 
oscillatory linear motion pattern, implemented in MAT-
LAB R2018a (The Mathworks, Natick, MA, USA). The 
position of the catheter tip was described as linear motion 
in the same direction. Stent lengths were computed in this 
simulation by finding the first intersection point between the 
oscillatory line describing the distal stent edge position and 
the straight line of the catheter tip position, and similarly, 
between the last intersection point of the proximal stent edge 
position and catheter tip (Fig. 2a). The distance between 
these two intersection points was taken to be the simulated 
stent length. Asynchronous acquisition was studied by vary-
ing the time offset of the catheter tip trajectory relative to the 
cardiac cycle in 1 ms increments, accumulating the results 
and computing descriptive statistics. Heart rates between 
50 and 100 beats per minute and tissue velocities from 10to 
40 mm/s were simulated. Motion parameters (speed, fre-
quency, amplitude, rest time) were chosen to simulate human 
cardiac motion, modelled on tissue velocities measured in 
M-mode echocardiography and angiography [19, 23].
In vitro simulation
Reproducible, controlled cardiac motion was simulated by 
mounting a vessel-mimicking tube (inner diameter 3.0 mm, 
PVC) on a linear motor stage (EACM6D10AZAC, Oriental 
Motor Co. Ltd., Tokyo, Japan). A 5.0 × 26 mm coronary 
stent (Resolute Onyx™, Medtronic, Minneapolis, Minne-
sota, USA) was deployed inside the tube, which was then 
filled with water, in order to acquire the OCT images in a 
medium with a refractive index very close to that of saline 
solution. The linear motor stage was programmed to simu-
late cardiac motion of a vessel relative to the imaging cathe-
ter by translating the tube along its longitudinal axis (Fig. 3).
The length of the stent was measured with a calliper and 
by performing repeated pullbacks (N = 10) without motion 
with a commercial OCT system. In the OCT images, the 
length of the stent was measured by counting the number 
of frames that contained at least one stent strut and aver-
aging the results of all pullbacks. The pullback speed was 
18 mm/s, frame pitch 100 µm.
A selection of motion parameter sets that were simulated 
in Matlab were programmed in this setup. For every selec-
tion of parameters, four sets of OCT scans were performed 
0 1 2 3 4 5
time (s)
0
10
20
30
40
50
60
70
80
90
100
110
po
sit
io
n 
(m
m)
Heartbeat OCT 100 mm/s pullback
Commercial OCT 18 mm/s pullback
Commercial OCT 36 mm/s pullback
stent distal end
stent proximal end
0 0.2 0.4 0.6 0.8 1
acquisition start delay (s)
21
22
23
24
25
26
27
m
e
a
su
re
d 
st
en
t l
en
gt
h 
(m
m)
Heartbeat OCT 100 mm/s pullback
Commercial OCT 18 mm/s pullback
Commercial OCT 36 mm/s pullback
a b
Fig. 2  Cardiac motion numerical  simulation. a Simulation outline: 
the lines depict the  position in time of stent edges and OCT cath-
eters tip in time. b Simulation result:  measured stent length values 
obtained at different pullback speeds with random trigger starts (true 
value 24 mm, 60 BPM, tissue velocity 10 mm/s). The black oval indi-
cates the range of acquisition delays where Heartbeat OCT completes 
the pullback within the resting phase
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with both the commercial OCT system (pullback speeds 18 
and 36 mm/s, frame pitch 100 and 200 µm) and with the 
Heartbeat OCT system (pullback speed 100 mm/s, frame 
pitch 33 µm), with and without synchronisation of the start 
of the pullback (Fig. 4) to the cardiac cycle. For every selec-
tion of motion parameters, 20 pullbacks were recorded.
Data analysis
To quantify the distortion introduced by the movement of the 
tube, the length of the deployed stent was measured in every 
pullback. We computed, for each set of pullbacks, average 
length, standard deviation and root mean square deviation 
from the real value. Length errors are reported as (signed) 
mean ± standard deviation.
In vivo imaging of stents
The in  vivo preclinical experiments were approved 
by the Erasmus MC animal ethics committee (DEC-
EMC3125(109–12-25)) and the animals were treated 
according to National Institutes of Health Guide for the care 
and use of laboratory animals [24]. The animals were adult 
(3 years old) Familial-hypercholesterolemia Bretonchelles 
Meishan (FBM) pigs [25] (n = 2, castrated males).The pigs 
were fed with a high-fat diet for the 9 months preceding the 
experiments.
Twenty-eight days before the imaging experiment, stents 
(3.0 × 13 mm, Orsiro, Biotronik, Lake Oswego, Oregon, 
USA) were implanted in the left anterior descending (LAD) 
at a location with early-stage plaque. All animals were 
treated with acetylsalicylic acid 250 mg and clopidogrel 
300  mg (Plavix, Sanofi-Aventis, Paris, France) during 
follow up and 75 mg clopidogrel daily until the imaging 
experiment.
After an overnight fast, sedation was done with xyla-
zine (2.25 mg/kg, 20 mg/ml, Sedazine, AST Farma, Oude-
water, The Netherlands), Zoletil 100 (6 mg/kg, 100 mg/
ml, Virbac, Barneveld, The Netherlands), injected intra-
muscularly. Then pentobarbital 50 mg/ml (10 to 15 mg/
kg/h, Faculty Pharmacy Utrecht, The Netherlands) was 
injected and the pig was intubated. Oxygen (25–30% 
Fig. 3  Bench-top experiment schematic: a coronary stent in deployed 
in a PVC tube; the tube translates longitudinally during the OCT 
acquisition, simulating relative motion between imaging catheter and 
the imaged vessel
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Fig. 4  Heartbeat OCT triggering in the bench-top experiment, tissue speed. a 10 mm/s, b 40 mm/s
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v/v) and nitrogen (75–80% v/v) were provided through 
ventilation to keep blood gas values within physiological 
ranges. To maintain anaesthesia, isoflurane (1–2.5% v/v) 
was administered through ventilation.
250  mg of acetylsalicylic acid (Aspegic, Sanofi-
Aventis) and 10,000 units of heparin (Heparin Leo, Leo 
Pharma, Amsterdam, The Netherlands) were administered 
through a sheath deployed in the carotid artery of the 
animal, with an extra dose of 5000 units of heparin every 
hour.
Through the same sheath, an 8 Fr JL3.5 guiding cath-
eter (Boston Scientific, Marlborough, Massachusetts, 
USA) was inserted into the ostium of the LAD coronary 
artery. To induce vasodilation, isosorbide mononitrate 
(0.04 mg/kg, 1 mg/ml) was injected through the guiding 
catheter.
During the imaging experiment, the stents implanted 
in the LAD arteries of both animals, were imaged using 
both the commercial OCT system and the Heartbeat OCT 
system. The imaging catheter of the commercial OCT 
system (Dragonfly™ Duo, Abbott) was inserted over 
a 0.014″ 190  cm guidewire (HI-TORQUE PILOT 50, 
Abbott), while the Heartbeat OCT catheter was placed 
with a delivery catheter (GuideLiner V3 catheter, Vascu-
lar Solutions, Minneapolis, Minnesota, USA), as it is not 
guidewire-compatible. After the experiment, the animals 
were sacrificed and the coronary arteries were excised 
from the heart and frozen for further analysis.
Micro CT imaging
In the frozen state the explanted vessels were imaged with an 
X-ray micro-computed tomography (μCT) scanner (Quan-
tum FX, Perkin Elmer, Waltham, Massachusetts, USA), to 
provide a reference length measurement for the OCT images. 
The voxel size was set at 80 µm.
Stent length comparison
The length of the deployed stent was measured in every 
OCT pullback, with the same modalities of the in vitro 
experiment. Using the proprietary software provided with 
the micro-CT scanner, the length of the frozen stents was 
measured as well and used as a reference. These lengths 
were then compared.
Results
Comparison of clinical OCT‑measured lengths 
to nominal lengths
Regression analysis and Bland–Altman plots of the OCT-
measured and nominal stents lengths are reported in Fig. 5. 
The nominal stent length ranged from 8 to 40 mm, average 
21.7 ± 9.3 mm. The OCT-measured lengths varied from 5.2 
to 47 mm, average 22.8 ± 9.6 mm. The average difference 
between the OCT-measured lengths and the nominal values 
was 1.1 ± 1.6 mm (r = 0.986, p < 0.001). The absolute maxi-
mum overestimated longitudinal measurement was 7.6 mm, 
the maximum underestimated measurement was 5.5 mm. 
Larger errors were observed in the RCA (1.6 ± 2.4 mm) com-
pared to the LAD (1.0 ± 1.3 mm) and LCX (0.9 ± 1.2 mm). 
There was no difference in stent length measurement accu-
racy between 18 mm/s (N = 40) and 36 mm/s (N = 61) pull-
back speed.
Fig. 5  Nominal vs OCT-meas-
ured stent lengths in clinical 
data. a Regression analysis, b 
Bland–Altman plot
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Cardiac motion simulation experiments
Numerical simulation of OCT-measured stent lengths 
showed differences comparable to the clinically observed 
deviations from nominal length (Fig. 6). For low tissue 
velocities, the mean error vanished for all stent lengths 
and heart rates and the standard deviation of the difference 
between observed and nominal lengths was approximately 
2 mm. The spread in the data increases with tissue veloc-
ity, and is slightly larger for the 36 mm/s pullback speed 
compared to 18 mm/s. The measured stent lengths are the 
most accurate with 100 mm/s pullback speed, even without 
synchronisation.
In vitro, the length of the deployed stent measured by 
OCT without motion was 25.3 ± 0.2 mm, in agreement with 
the calliper measurement of 25.35 mm. As in the numeri-
cal simulation, the relative movement between the stent and 
the imaging catheter introduces a measurement error, that 
increases in average and standard deviation at higher tissue 
velocity (Table 1). Synchronized Heartbeat OCT pullbacks 
showed a lower dispersion of the measurements. The acqui-
sitions were triggered to coincide with the motion phase 
mimicking diastole, with minimal tissue motion. Thanks to 
the higher pullback speed, the Heartbeat OCT, for a range of 
pullback start delays, acquires the entire stent before the sub-
sequent movement cycle starts, returning a measured length 
equal to the nominal value (Fig. 2b). Even with short cycles 
(100 BPM) when the zero-motion period is too short to 
image the entire stent in stationary conditions, the standard 
deviation of the measures is low due to the synchronisation.
In vivo imaging of stents
In two experiments, the stents implanted in the LAD of 
two swine were imaged. In each pig, one pullback with the 
commercial system and one with the Heartbeat OCT sys-
tem were performed. In the first pig, the triggering of the 
Heartbeat OCT was synchronized on the animal ECG, and 
started 0.3 s after the R-peak; in the second the acquisition 
was asynchronous.
The delay used for the synchronized pullback was set 
heuristically based on motion patterns analysed from the 
angiographic images. The heart rate of the animals was 54 
to 65 BPM in the first pig and 60 to 74 BPM in the second 
pig. One of the two data sets acquired with the Heartbeat 
OCT presented an incomplete flushing artefact, all other 
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Fig. 6  Numerical simulation of OCT-measured stent lengths, error ± standard deviation vs heart rate, for different tissue motion speeds. Nominal 
stent length 24 mm
Table 1  In vitro experiment 
results, reported as average 
measurement error ± standard 
deviation
Tube speed = 10 mm/s
60 cycles/minute
Tube speed = 40 mm/s
60 cycles/minute
Commercial OCT pullback speed 18 mm/s − 0.1 ± 1.2 mm 1.5 ± 4.5 mm
Commercial OCT pullback speed 36 mm/s 0.3 ± 1.3 mm − 0.5 ± 4.9 mm
Heartbeat OCT pullback speed 100 mm/s − 0.30 ± 0.03 mm − 0.1 ± 0.1 mm
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had adequate flush. Three-dimensional renderings of the 
imaged vessels are shown in Fig. 7. While the cross-sec-
tional images (Fig. 7c and 7g) are affected by shadows due 
to the motor wires in the current design of the catheter, the 
longitudinal and 3D renderings of the data show a wealth 
of detail compared to the commercial system. In particu-
lar, because of improved longitudinal sampling, individual 
stent struts are clearly resolved, embedded in low-signal 
neo-intimal tissue (Fig. 7h), which has been associated 
with low cellularity and proteoglycan-rich tissue [26].
The recorded length of the stents are reported in 
Table 2. Without timed acquisition, the length measure-
ment error in this 13 mm stent was about 0.9 mm in both 
the conventional and Heartbeat OCT systems. The stent 
length as measured in the synchronized Heartbeat OCT 
pullback was longer by 0.2 mm compared to the length 
measured in the μCT data, while the commercial system 
overestimated it by 1.2 mm.
Discussion
In this study, we investigated the impact of cardiac motion 
on longitudinal measurements in OCT pullbacks. We 
found errors of typically 5.0%, highest in RCA (7.4%), 
lowest in LCX (4.1%), with outliers up to > 5 mm, in clini-
cal data, independent of pullback speed. Similar errors 
could be produced by cardiac motion simulation and OCT 
imaging with both a commercial system and a custom-
made OCT machine that performs pullbacks at high speed 
Fig. 7  Cross-section images 
and 3D reconstructions of stents 
implanted in the LAD of two 
atherosclerotic swine. Top: 
OCT start synchronized to the 
ECG of the animal; bottom: 
asynchronous pullback
Table 2  In vivo stent lengths, 
obtained with a µCT scanner, 
a commercial OCT system and 
the Heartbeat OCT system
Nominal 
(mm)
Micro-CT (mm) Commercial 
OCT (mm)
Deviation Heartbeat OCT Asynchronous 
high-speed OCT
Deviation
13 12.80 14.0 1.2 13.0 0.2
13 12.32 11.4 − 0.9 11.5 − 0.8
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(Heartbeat OCT). Analysis of in vitro simulations, cor-
roborated by illustrative in vivo measurements, demon-
strated that high-speed (100 mm/s) pullbacks combined 
with synchronized acquisition can perform accurate length 
measurements in a moving vessel. The observed standard 
deviations of the (zero-mean) error in longitudinal meas-
urements are smaller by an order of magnitude with the 
use of high-speed pullback in combination with ECG trig-
gering, compared to asynchronous acquisition at conven-
tional speeds. This may enable length measurements with 
an accuracy better than 100 μm in vivo, less than the frame 
pitch of today’s OCT systems.
In OCT-guided PCI, errors in length measurement may 
result in significant sizing and positioning issues. For 
instance, a stent in a side branch that is slightly too long 
or positioned too proximal may protrude in the lumen of 
the main branch, giving rise to increased risk of follow-
up events [27] and potential complications when crossing 
wires in later procedures.
Our simulations confirm that the longitudinal measure-
ment error increases with greater relative motion between 
the vessel and the catheter. This motion may be highly 
variable in practice, depending on the heart rate, cardiac 
phase, actual tissue displacement during systole, but also 
on the selectivity of the guiding catheter used to deliver 
the OCT catheter. A well-seated guiding catheter will 
move with the ostium and thus eliminate much of the rela-
tive motion between vessel and imaging catheter.
Comparison of OCT‑measured lengths to nominal 
lengths
We assessed the impact of motion artefacts in clinical OCT 
imaging in coronary arteries by measuring the length of 
implanted stents on OCT pullbacks and comparing those 
to the nominal length. In 2013, Liu et al. [19] conducted 
a similar analysis, with a comparable dataset. They found 
a smaller average difference of 0.15 mm, with a similar 
standard deviation of 0.68 mm. We attribute this small dis-
crepancy to a different definition of stent edge: the first/last 
frame containing any number of stent struts in the present 
study, versus a requirement of at least 180° of continuous 
arc with visible struts in [19].
We performed a systematic study of cardiac motion and 
longitudinal measurement error using both a numerical model 
of catheter motion relative to a stented vessel and a physical 
bench-top implementation of this model. Both simulations 
showed the same trends: unbiased errors and increasing disper-
sion with heart rate and tissue motion. Inspection of the error 
distributions in both simulations showed that these are far from 
normal, in fact frequently bimodal. Thus, descriptive statis-
tics in terms of the mean and standard deviation provide only 
a partial representation of the actual errors that may occur. 
The absolute errors measured in the bench top system were 
smaller by a factor of approximately two than the numerical 
simulations, and are closer to the clinically observed length 
deviations. We have no clear explanation for this difference.
The observations we made in the small number of in vivo 
pullbacks confirm that it is possible to make accurate stent 
length measurements during the diastolic phase of the cardiac 
cycle, and that asynchronous or slower acquisition degrade the 
reliability of the measurement. The small number of animals 
in this study precludes a quantitative analysis of in vivo imag-
ing performance.
In vivo imaging of stents
The data in Fig. 7 are the first images of stents in vivo acquired 
with the Heartbeat OCT system, showing neo-intima forma-
tion in this porcine model of coronary atherosclerosis in one 
animal, while in another there was minimal coverage of the 
struts at 28 days after implantation. The images show a high 
level of detail.
The Heartbeat OCT catheter is a prototype which cannot be 
directly applied for clinical imaging. Several improvements, 
related to catheter size, deliverability and the presence of shad-
ows in the image, will be implemented in future versions of 
the device.
ECG triggering and a higher acquisition speed improve the 
longitudinal fidelity of OCT data sets, overcoming limitations 
such as cardiac motion artefacts and undersampling that affect 
length measurements and volumetric renderings in conven-
tional implementations of the technology.
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